RT Journal Article
SR Electronic
T1 Lymphocytopaenia is associated with severe SARS-CoV-2 disease: A Systematic Review and Meta-Analysis of Clinical Data
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.14.20064659
DO 10.1101/2020.04.14.20064659
A1 Brown, Robin
A1 Barnard, Jane
A1 Harris-Skillman, Eva
A1 Harbinson, Bronwen
A1 Dunne, Beata
A1 Drake, Jonathan
A1 Roche, Sophie
A1 Harris, Edward
A1 Gunnell, James
A1 Frost, Joshua
A1 Angus, Brian
A1 Hodgson, Susanne H
YR 2020
UL http://medrxiv.org/content/early/2020/04/17/2020.04.14.20064659.abstract
AB Background Most patients infected by SARS-CoV-2 have favourable outcomes, however some develop severe disease which may progress to acute respiratory distress syndrome, multi-organ failure, and death. Markers that could predict patients at risk of poor outcomes would be extremely useful clinically. Evidence has emerged that low lymphocyte count is associated with increased disease severity.Methods We performed a systematic review and meta-analysis to assess the association between lymphocyte count and severity of SARS-CoV-2 associated clinical disease.Results Seven papers were included in the meta-analysis. These papers included data from 2083 patients, 25% (n=521) with severe SAR-CoV-2 disease and 75% (n=1562) with non-severe SAR-CoV-2 disease. Heterogenicity was seen in the definition of severe disease. Metanalysis produced metamedians of 1×109/L (95% CI 1-1.1) and 0.7×109/L (95% CI 0.63-0.8) lymphocytes for patients with non-severe and severe disease respectively (p-value of p=0.006 Wilcoxon test). Calculation of metamedians from the two papers classifying severe disease according to death alone gave 1.1 1×109/L lymphocytes (95% CI 1.0-1.1) for ‘survivors’ (n=163) and 0.63 1×109/L lymphocytes (95% CI 0.60-0.63) for ‘non-survivors’ (n=253) of SAR-CoV-2 disease.Conclusions Lower lymphocyte counts are significantly associated with more severe disease in patients with SARS-CoV-2 infection. Lymphocytopenia may therefore be useful laboratory measure to allow prognostication of patients presenting with SARS-CoV-2 infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received for this workAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data used in the study is available in the publications used for the meta-analysis